Scioderm, Inc. Named a 2013 "Fierce Top 15" Company by FierceBiotech
'One of the most promising private biotechnology companies in the industry'
DURHAM, N.C., Sept. 24, 2013 /PRNewswire/ -- Scioderm, Inc., a biopharmaceutical company focused on the development of innovative therapies for treating rare diseases with high unmet need, has been selected by FierceBiotech as one of their "Fierce 15" for 2013. The "Fierce 15" is FierceBiotech's annual list of the top 15 emerging companies in the biotech industry, thus designating Scioderm, Inc. as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's eleventh annual "Fierce 15" selection.
"In record time Scioderm has posted promising early efficacy data on a therapy for a rare and terrible disease, garnered a significant round of venture cash, earned a coveted breakthrough therapy designation at the FDA for its therapy and now plans to mount a critical trial in coming months," says John Carroll, editor of FierceBiotech. "In many ways Scioderm epitomizes what we mean by the word 'fierce.'"
"We are proud to join this prestigious group of innovative companies and for our team's recognition as a Fierce 15 Company," said Robert Ryan., Ph.D., President and Chief Executive Officer of Scioderm. "There is a tremendous need for novel treatment options for treating the debilitating skin effects in patients with Epidermolysis Bullosa. The Scioderm team is working passionately to provide patients a new therapeutic alternative, in a disease with no currently effective treatments."
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition.
An internationally recognized daily newsletter reaching more than 100,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
A complete list of "Fierce 15" companies – the online newsletter's eleventh annual selection – is available online at FierceBiotech.com.
Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address critical medical needs in the treatment of rare diseases. Scioderm's main focus is the treatment of Epidermolysis Bullosa (EB). SD-101, its leading therapy for the treatment of skin effects in patients with Epidermolysis Bullosa, is currently in clinical trials. SD-101 is a topical cream that has previously demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes. Additional information about Scioderm can be found at www.sderm.com.
FierceBiotech is the biotech industry's daily monitor – a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signing up is free.
Chief Operating Officer
More by this Source
Scioderm Appoints Orphan Product Executives to Board of Directors
Dec 02, 2013, 08:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.